Latest Insider Transactions at Artivion, Inc. (AORT)
This section provides a real-time view of insider transactions for Artivion, Inc. (AORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARTIVION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARTIVION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
226
-0.25%
|
$5,424
$24.44 P/Share
|
|
Mar 05
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
359
-0.12%
|
$8,616
$24.44 P/Share
|
|
Mar 05
2021
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,487
-0.46%
|
$35,688
$24.44 P/Share
|
|
Mar 05
2021
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
205
-0.91%
|
$4,920
$24.44 P/Share
|
|
Mar 05
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
SELL
Payment of exercise price or tax liability
|
Direct |
304
-0.89%
|
$7,296
$24.44 P/Share
|
|
Mar 01
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
13,619
-12.99%
|
$340,475
$25.53 P/Share
|
|
Feb 23
2021
|
Franz Peter Barthold VP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
704
-5.41%
|
$17,600
$25.41 P/Share
|
|
Feb 23
2021
|
Franz Peter Barthold VP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+19.63%
|
-
|
|
Feb 23
2021
|
Scott B Capps VP, Clinical Research |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-0.36%
|
$14,075
$25.41 P/Share
|
|
Feb 23
2021
|
Scott B Capps VP, Clinical Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+2.0%
|
-
|
|
Feb 23
2021
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
945
-1.14%
|
$23,625
$25.41 P/Share
|
|
Feb 23
2021
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,335
+6.06%
|
-
|
|
Feb 23
2021
|
Matthew A Getz VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-5.59%
|
$14,075
$25.41 P/Share
|
|
Feb 23
2021
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+23.96%
|
-
|
|
Feb 23
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-1.07%
|
$24,750
$25.41 P/Share
|
|
Feb 23
2021
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,589
+5.68%
|
-
|
|
Feb 23
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
619
-0.59%
|
$15,475
$25.41 P/Share
|
|
Feb 23
2021
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,493
+3.21%
|
-
|
|
Feb 23
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,237
-0.42%
|
$30,925
$25.41 P/Share
|
|
Feb 23
2021
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,987
+2.3%
|
-
|
|
Feb 23
2021
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,383
-1.35%
|
$109,575
$25.41 P/Share
|
|
Feb 23
2021
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
28,415
+8.02%
|
-
|
|
Feb 23
2021
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-2.44%
|
$14,075
$25.41 P/Share
|
|
Feb 23
2021
|
Dennis B Maier SVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+12.09%
|
-
|
|
Feb 23
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
SELL
Payment of exercise price or tax liability
|
Direct |
900
-2.58%
|
$22,500
$25.41 P/Share
|
|
Feb 23
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
BUY
Grant, award, or other acquisition
|
Direct |
5,081
+12.71%
|
-
|
|
Feb 17
2021
|
Franz Peter Barthold VP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,548
+26.53%
|
-
|
|
Feb 17
2021
|
Scott B Capps VP, Clinical Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,548
+2.28%
|
-
|
|
Feb 17
2021
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,024
+7.22%
|
-
|
|
Feb 17
2021
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,725
+35.06%
|
-
|
|
Feb 17
2021
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
21,302
+11.25%
|
-
|
|
Feb 17
2021
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,725
+3.52%
|
-
|
|
Feb 17
2021
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,801
+2.62%
|
-
|
|
Feb 17
2021
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,125
+10.02%
|
-
|
|
Feb 17
2021
|
Dennis B Maier SVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+16.38%
|
-
|
|
Feb 17
2021
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
7,197
-15.99%
|
$172,728
$24.68 P/Share
|
|
Feb 17
2021
|
Dennis B Maier SVP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
6,630
+22.22%
|
$139,230
$21.55 P/Share
|
|
Feb 17
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
BUY
Grant, award, or other acquisition
|
Direct |
5,355
+15.22%
|
-
|
|
Dec 15
2020
|
Harvey Morgan Director |
BUY
Bona fide gift
|
Indirect |
2,080
+4.65%
|
-
|
|
Dec 15
2020
|
Harvey Morgan Director |
SELL
Bona fide gift
|
Direct |
2,080
-3.99%
|
-
|
|
Dec 15
2020
|
Scott B Capps VP, Clinical Research |
SELL
Open market or private sale
|
Direct |
8,366
-5.33%
|
$175,686
$21.34 P/Share
|
|
Dec 15
2020
|
Scott B Capps VP, Clinical Research |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.99%
|
$90,000
$9.97 P/Share
|
|
Dec 14
2020
|
Amy Horton VP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
1,375
-1.38%
|
$28,875
$21.25 P/Share
|
|
Dec 14
2020
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,666
+6.27%
|
$59,994
$9.97 P/Share
|
|
Dec 14
2020
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
1,843
-10.19%
|
$38,703
$21.85 P/Share
|
|
Dec 14
2020
|
Ronald D Mc Call Director |
SELL
Open market or private sale
|
Direct |
4,638
-3.48%
|
$97,398
$21.79 P/Share
|
|
Dec 10
2020
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Open market or private sale
|
Direct |
16,666
-5.57%
|
$383,318
$23.0 P/Share
|
|
Dec 10
2020
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+5.28%
|
$149,994
$9.97 P/Share
|
|
Dec 01
2020
|
Franz Peter Barthold VP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
654
-9.43%
|
$13,080
$20.93 P/Share
|
|
Dec 01
2020
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
6,666
-6.69%
|
$133,320
$20.78 P/Share
|